These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 28532436)

  • 1. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study.
    Tazi A; Lorillon G; Haroche J; Neel A; Dominique S; Aouba A; Bouaziz JD; de Margerie-Melon C; Bugnet E; Cottin V; Comont T; Lavigne C; Kahn JE; Donadieu J; Chevret S
    Orphanet J Rare Dis; 2017 May; 12(1):95. PubMed ID: 28532436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
    Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
    Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.
    Minkov M
    Paediatr Drugs; 2011 Apr; 13(2):75-86. PubMed ID: 21351807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Langerhans Cell Histiocytosis (LCH) in Egyptian Children: Does Reactivation Affect the Outcome?
    Sedky MS; Rahman HA; Moussa E; Taha H; Raafat T; Hassanein O
    Indian J Pediatr; 2016 Mar; 83(3):214-9. PubMed ID: 26133729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of adult multisystemic Langerhans cell histiocytosis with psoralen-UV-A, prednisolone, mercaptopurine, and vinblastine.
    von Stebut E; Schadmand-Fischer S; Bräuninger W; Kreft A; Doberauer C; Steinbrink K
    Arch Dermatol; 2008 May; 144(5):649-53. PubMed ID: 18490592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nationwide retrospective study.
    Ng Wing Tin S; Martin-Duverneuil N; Idbaih A; Garel C; Ribeiro M; Parker JL; Defachelles AS; Lambilliotte A; Barkaoui M; Munzer M; Gardembas M; Sibilia J; Lutz P; Fior R; Polak M; Robert A; Aumaitre O; Plantaz D; Armari-Alla C; Genereau T; Berard PM; Talom GN; Pennaforte JL; Le Pointe HD; Barthez MA; Couillault G; Haroche J; Mokhtari K; Donadieu J; Hoang-Xuan K;
    Orphanet J Rare Dis; 2011 Dec; 6():83. PubMed ID: 22151964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of children younger than 24 months with langerhans cell histiocytosis and bone involvement: a report from a single institution.
    Kamath S; Arkader A; Jubran RF
    J Pediatr Orthop; 2014 Dec; 34(8):825-30. PubMed ID: 25387157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.
    Gadner H; Minkov M; Grois N; Pötschger U; Thiem E; Aricò M; Astigarraga I; Braier J; Donadieu J; Henter JI; Janka-Schaub G; McClain KL; Weitzman S; Windebank K; Ladisch S;
    Blood; 2013 Jun; 121(25):5006-14. PubMed ID: 23589673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis.
    Gadner H; Grois N; Arico M; Broadbent V; Ceci A; Jakobson A; Komp D; Michaelis J; Nicholson S; Pötschger U; Pritchard J; Ladisch S;
    J Pediatr; 2001 May; 138(5):728-34. PubMed ID: 11343051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Langerhans cell histiocytosis in children less than 2 years of age.
    Kusuma Kumary P; Priyakumari T; Chellam VG; James FV; Nair MK
    Indian Pediatr; 1999 Jan; 36(1):29-36. PubMed ID: 10709120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe isolated pulmonary Langerhans cell histiocytosis in a 6-year-old girl.
    Schulze J; Kitz R; Grüttner HP; Schmidt H; Zielen S
    Eur J Pediatr; 2004 Jun; 163(6):320-2. PubMed ID: 15346914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
    Narula G; Pradhan ND; Arora B; Banavali SD
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating cell-free BRAF
    Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
    Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society.
    Weitzman S; Braier J; Donadieu J; Egeler RM; Grois N; Ladisch S; Pötschger U; Webb D; Whitlock J; Arceci RJ
    Pediatr Blood Cancer; 2009 Dec; 53(7):1271-6. PubMed ID: 19731321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry.
    Minkov M; Steiner M; Pötschger U; Aricò M; Braier J; Donadieu J; Grois N; Henter JI; Janka G; McClain K; Weitzman S; Windebank K; Ladisch S; Gadner H;
    J Pediatr; 2008 Nov; 153(5):700-5, 705.e1-2. PubMed ID: 18589441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adult Langerhans' cell histiocytosis with multisystem involvement: A case report.
    Kim SS; Hong SA; Shin HC; Hwang JA; Jou SS; Choi SY
    Medicine (Baltimore); 2018 Nov; 97(48):e13366. PubMed ID: 30508929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late outcomes in children with Langerhans cell histiocytosis.
    Chow TW; Leung WK; Cheng FWT; Kumta SM; Chu WCW; Lee V; Shing MMK; Li CK
    Arch Dis Child; 2017 Sep; 102(9):830-835. PubMed ID: 28442470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LCH-I: a randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. The Histiocyte Society.
    Ladisch S; Gadner H; Aricò M; Broadbent V; Grois N; Jacobson A; Komp D; Nicholson HS
    Med Pediatr Oncol; 1994; 23(2):107-10. PubMed ID: 8202031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.